These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

311 related items for PubMed ID: 2152774

  • 1. Evaluation of ricin A chain-containing immunotoxins directed against the CD30 antigen as potential reagents for the treatment of Hodgkin's disease.
    Engert A, Burrows F, Jung W, Tazzari PL, Stein H, Pfreundschuh M, Diehl V, Thorpe P.
    Cancer Res; 1990 Jan 01; 50(1):84-8. PubMed ID: 2152774
    [Abstract] [Full Text] [Related]

  • 2. Antitumor effects of ricin A chain immunotoxins prepared from intact antibodies and Fab' fragments on solid human Hodgkin's disease tumors in mice.
    Engert A, Martin G, Pfreundschuh M, Amlot P, Hsu SM, Diehl V, Thorpe P.
    Cancer Res; 1990 May 15; 50(10):2929-35. PubMed ID: 1692251
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. [New perspectives in oncology: is selective destruction of tumor cells with immunotoxins in Hodgkin's disease an additional therapeutic alternative?].
    Engert A, Gottstein C, Winkler U, Schön G, Amlot P, Thorpe P, Diehl V.
    Med Klin (Munich); 1992 Oct 15; 87(10):503-9. PubMed ID: 1461215
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. The in vivo anti-tumor activity of immunotoxins containing two versus one deglycosylated ricin A chains.
    Ghetie V, Engert A, Schnell R, Vitetta ES.
    Cancer Lett; 1995 Nov 27; 98(1):97-101. PubMed ID: 8529213
    [Abstract] [Full Text] [Related]

  • 9. Idiotype vaccine against Hodgkin's lymphoma: generation and characterization of an anti-idiotypic monoclonal antibody against the Hodgkin-associated (anti-CD 30) monoclonal antibody HRS-3.
    Pohl C, Sieber M, Diehl V, Pfreundschuh M.
    Anticancer Res; 1991 Nov 27; 11(3):1115-24. PubMed ID: 1653553
    [Abstract] [Full Text] [Related]

  • 10. A Phase I study with an anti-CD30 ricin A-chain immunotoxin (Ki-4.dgA) in patients with refractory CD30+ Hodgkin's and non-Hodgkin's lymphoma.
    Schnell R, Staak O, Borchmann P, Schwartz C, Matthey B, Hansen H, Schindler J, Ghetie V, Vitetta ES, Diehl V, Engert A.
    Clin Cancer Res; 2002 Jun 27; 8(6):1779-86. PubMed ID: 12060617
    [Abstract] [Full Text] [Related]

  • 11. Clinical evaluation of ricin A-chain immunotoxins in patients with Hodgkin's lymphoma.
    Schnell R, Borchmann P, Staak JO, Schindler J, Ghetie V, Vitetta ES, Engert A.
    Ann Oncol; 2003 May 27; 14(5):729-36. PubMed ID: 12702527
    [Abstract] [Full Text] [Related]

  • 12. Evaluation of four CD22 antibodies as ricin A chain-containing immunotoxins for the in vivo therapy of human B-cell leukemias and lymphomas.
    Shen GL, Li JL, Ghetie MA, Ghetie V, May RD, Till M, Brown AN, Relf M, Knowles P, Uhr JW.
    Int J Cancer; 1988 Nov 15; 42(5):792-7. PubMed ID: 3263328
    [Abstract] [Full Text] [Related]

  • 13. In vivo therapy of the BCL1 tumor: effect of immunotoxin valency and deglycosylation of the ricin A chain.
    Fulton RJ, Uhr JW, Vitetta ES.
    Cancer Res; 1988 May 01; 48(9):2626-31. PubMed ID: 3258547
    [Abstract] [Full Text] [Related]

  • 14. Pharmacokinetics of tumor-reactive immunotoxins in tumor-bearing mice: effect of antibody valency and deglycosylation of the ricin A chain on clearance and tumor localization.
    Fulton RJ, Tucker TF, Vitetta ES, Uhr JW.
    Cancer Res; 1988 May 01; 48(9):2618-25. PubMed ID: 3258546
    [Abstract] [Full Text] [Related]

  • 15. A phase I study of combination therapy with immunotoxins IgG-HD37-deglycosylated ricin A chain (dgA) and IgG-RFB4-dgA (Combotox) in patients with refractory CD19(+), CD22(+) B cell lymphoma.
    Messmann RA, Vitetta ES, Headlee D, Senderowicz AM, Figg WD, Schindler J, Michiel DF, Creekmore S, Steinberg SM, Kohler D, Jaffe ES, Stetler-Stevenson M, Chen H, Ghetie V, Sausville EA.
    Clin Cancer Res; 2000 Apr 01; 6(4):1302-13. PubMed ID: 10778955
    [Abstract] [Full Text] [Related]

  • 16. Specific activation of the prodrug mitomycin phosphate by a bispecific anti-CD30/anti-alkaline phosphatase monoclonal antibody.
    Sahin U, Hartmann F, Senter P, Pohl C, Engert A, Diehl V, Pfreundschuh M.
    Cancer Res; 1990 Nov 01; 50(21):6944-8. PubMed ID: 2170012
    [Abstract] [Full Text] [Related]

  • 17. Ber-H2 (anti-CD30)-saporin immunotoxin: a new tool for the treatment of Hodgkin's disease and CD30+ lymphoma: in vitro evaluation.
    Tazzari PL, Bolognesi A, de Totero D, Falini B, Lemoli RM, Soria MR, Pileri S, Gobbi M, Stein H, Flenghi L.
    Br J Haematol; 1992 Jun 01; 81(2):203-11. PubMed ID: 1322690
    [Abstract] [Full Text] [Related]

  • 18. Experimental treatment of human Hodgkin's disease with ricin A-chain immunotoxins.
    Engert A, Gottstein C, Winkler U, Amlot P, Pileri S, Diehl V, Thorpe P.
    Leuk Lymphoma; 1994 May 01; 13(5-6):441-8. PubMed ID: 8069189
    [Abstract] [Full Text] [Related]

  • 19. Cytotoxic activity of ricin A chain immunotoxins recognising cluster 1, w4 and 5A antigens associated with human small cell lung cancer.
    Wawrzynczak EJ, Derbyshire EJ, Henry RV, Parnell GD, Smith A, Waibel R, Stahel RA.
    Br J Cancer Suppl; 1991 Jun 01; 14():71-3. PubMed ID: 1645577
    [Abstract] [Full Text] [Related]

  • 20. Efficient transplantation of human non-T-leukemia cells into nude mice and induction of complete regression of the transplanted distinct tumors by ricin A-chain conjugates of monoclonal antibodies SN5 and SN6.
    Hara H, Luo Y, Haruta Y, Seon BK.
    Cancer Res; 1988 Aug 15; 48(16):4673-80. PubMed ID: 2969282
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.